Recursion Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was the recipient of some unusual options trading activity on Thursday. Investors bought 25,291 call options on the stock. This represents an increase of 50% compared to the typical daily volume of 16,872 call options.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 40,000 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $3.96, for a total transaction of $158,400.00. Following the sale, the director directly owned 6,218,287 shares of the company’s stock, valued at $24,624,416.52. This trade represents a 0.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 22,408 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $3.52, for a total value of $78,876.16. Following the completion of the transaction, the chief executive officer owned 2,072,890 shares in the company, valued at $7,296,572.80. The trade was a 1.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 122,408 shares of company stock worth $434,976. 6.65% of the stock is owned by corporate insiders.

Institutional Trading of Recursion Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. MCF Advisors LLC purchased a new stake in shares of Recursion Pharmaceuticals during the 2nd quarter worth approximately $27,000. Integral Investment Advisors Inc. purchased a new position in shares of Recursion Pharmaceuticals in the first quarter valued at $39,000. Sequoia Financial Advisors LLC purchased a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at $41,000. MQS Management LLC bought a new stake in Recursion Pharmaceuticals in the first quarter worth $41,000. Finally, Fund Advisors of America Inc FL bought a new stake in Recursion Pharmaceuticals in the second quarter worth $45,000. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Up 8.2%

Shares of RXRX stock opened at $3.83 on Friday. The stock has a market cap of $2.05 billion, a P/E ratio of -3.68 and a beta of 1.07. The company’s fifty day simple moving average is $3.26 and its two-hundred day simple moving average is $3.32. The company has a quick ratio of 5.03, a current ratio of 5.03 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals has a 52 week low of $2.77 and a 52 week high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The firm had revenue of $7.67 million during the quarter, compared to the consensus estimate of $10.97 million. Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.During the same period last year, the firm posted ($0.41) earnings per share. Analysts predict that Recursion Pharmaceuticals will post -0.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RXRX has been the topic of several recent analyst reports. Wall Street Zen raised Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 29th. Morgan Stanley set a $5.30 price target on Recursion Pharmaceuticals in a research note on Monday, August 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $8.06.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biotechnology company that uses artificial intelligence, automation, and large-scale biological experimentation to accelerate the discovery and development of medicines. Its technology platform, known as the Recursion Operating System, integrates data from biology, chemistry, imaging, and machine learning to identify potential drug candidates and better understand disease biology.

The company develops therapies for areas including oncology, rare diseases, and neurological disorders.